News

Events

Susana Minguet

Institute of Biology III, University of Freiburg
Group leader
+49 761-203-97663
Our research focuses on understanding the molecular mechanisms governing T and B lymphocyte activation. We investigate how αβ and γδ T lymphocytes transmit ligand-binding information across the plasma membrane through their antigen receptors and the signaling pathways that regulate their activation. Additionally, we explore the nano-organization of the B-cell antigen receptor and how defective B-cell activation contributes to immunopathologies. Bridging fundamental immunology with translational medicine, we focus on T cell-based cancer immunotherapy. Our work aims to harness CD3 diversity and refine synthetic chimeric antigen receptor (CAR) design to enhance CAR T-cell therapy. We also explore how the tumor microenvironment influences T-cell motility and how γδ T cells can be leveraged to optimize tumor immunotherapy. By uncovering key principles of lymphocyte signaling, we strive to advance cancer immunotherapy, autoimmune disease research, and immunodeficiency treatment, paving the way for next-generation immunotherapies.

10 selected publications

  • From TCR fundamental research to innovative chimeric antigen receptor design.
    Minguet S, Maus MV, Schamel WW (2024)
    Nat Rev Immunol
  • Kidins220 regulates the development of B cells bearing the λ light chain.
    Schaffer AM, Fiala GJ, Hils M, Natali E, Babrak L, Herr LA, Romero-Mulero MC, Cabezas-Wallscheid N, Rizzi M, Miho E, Schamel WWA, Minguet S (2024)
    Elife 13:e83943.
  • Harnessing CD3 diversity to optimize CAR T cells.
    Velasco Cárdenas RMH, Brandl SM, Meléndez AV*, Schlaak AE*, Buschky A, Peters T, Beier F, Serrels B, Taromi S, Raute K, Hauri S, Gstaiger M, Lassmann S, Huppa JB, Boerries M, Andrieux G, Bengsch B, Schamel WW, Minguet S (2023)
    Nat Immunol 24(12):2135-2149
  • Breast Cancer Stem Cell-Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands.
    Raute K, Strietz J*, Parigiani MA*, Andrieux G, Thomas OS, Kistner KM, Zintchenko M, Aichele P, Hofmann M, Zhou H, Weber W, Boerries M, Swamy M, Maurer J, Minguet S (2023)
    Cancer Immunol Res 11(6):810-829.
  • Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells.
    Meléndez AV, Velasco Cárdenas RM, Lagies S, Strietz J, Siukstaite L, Thomas OS, Tomisch J, Weber W, Kammerer B, Römer W*, Minguet S* (2022)
    Cell Mol Life Sci 79(10):513. *Shared corresponding author.
  • Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function.
    Hartl FA, Beck-Garcìa E, Woessner NM, Flachsmann LJ, Velasco Cárdenas RMH, Brandl SM, Taromi S, Fiala GJ, Morath A, Mishra P, Yousefi OS, Zimmermann J, Hoefflin N, Köhn M, Wöhrl BM, Zeiser R, Schweimer K, Günther S, Schamel WW*, Minguet S* (2020)
    Nat Immunol 21:902–913. *Shared corresponding author.
  • Caveolin-1-dependent nanoscale organization of the BCR regulates B cell tolerance.
    Minguet S*, Kläsener K, Schaffer AM, Fiala GJ, Osteso-Ibánez T, Raute K, Navarro-Lérida I, Hartl FA, Seidl M, Reth M, Del Pozo MA (2017)
    Nat Immunol 18(10):1150-1159. *Corresponding author
  • Caveolin-1 regulates TCR signal strength and regulatory T cell differentiation into alloreactive T cells
    Schönle A*, Hartl FA*, Mentzel J, Rauch KS, Wohlfeil SA, Noltner T, Hechinger AK, Melchinger W, Fehrenbach K, Guadamillas MC, Prestipino A, Follo M, Prinz G, Ruess AK, Pfeifer D, Pozo MA, Schmitt-Graeff A, Duyster J, Blazar BR, Schachtrup K, Minguet S* and Zeiser*(2016)
    Blood. doi: 10.1182/blood-2015-09-672428. *Shared first and shared corresponding author.
  • Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis Cell.
    Goetz JG*, Minguet S*, Navarro-Lerida I, Lazcano JJ, Samaniego R, Calvo E, Tello M, Osteso-Ibanez T, Pellinen T, Echarri A, Cerezo A, Klein-Szanto AJP, Garcia R, Keely PJ, Sanchez-Mateos P, Cukierman E, and Del Pozo MA (2021) doi: 10.1016/j.cell.2011.05.040. *Shared first author.
  • Full activation of the T cell receptor requires both clustering and conformational changes at CD3 Immunity.
    Minguet S, Swamy M, Alarcon B, Luescher IF, and Schamel WWA (2007) doi:10.1016/j.immuni.2006.10.019.